Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 7 May 2024 AM
With the leading drug in the radiopharmaceutical market in its arsenal, Novartis is devoting even more attention to these cancer treatments, with the acquisition of Mariana Oncology late last week.
The Swiss pharma giant agreed to buy the US-based pre-clinical stage biotech in a deal worth up to US$1.75 billion with the transaction offering a robust portfolio of radioligand therapies (RLTs) to treat a range of cancers such as breast, prostate and lung cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.